Predictive wild-type RAS/BRAF and pharmacogenetic biomarkers drive selection of metastatic colorectal cancer patients fit for intensive first-line FIr-C/FOx-C schedule adding cetuximab to triplet chemotherapy

被引：0
|
作者：
Russell, Mike
Lowenstein, Cassandra L.
Zhang, Xuqing
Roach, Jeremy
Song, Jianing
Nagilla, Rakesh
Orth, Peter
Tudor, Matt
Deng, Qiaolin
Sui, Zhihua
Strickland, Corey
Jolivette, Larry J.
Priestley, E. Scott
Mohammad, Helai P.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-A052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A052
引用
收藏
页数：2
相关论文
共 50 条
  • [41] The cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: An Italian healthcare payer perspective
    Patterson, K.
    Bhattacharyya, S.
    Personeni, N.
    Gebbia, V.
    Novelli, P.
    Di Matteo, S.
    Colombo, G.
    Pescott, C.
    ANNALS OF ONCOLOGY, 2019, 30 : 225 - 225
  • [42] Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
    Kienle, Dirk L.
    Dietrich, Daniel
    Ribi, Karin
    Wicki, Andreas
    Quagliata, Luca
    Winterhalder, Ralph C.
    Koeberle, Dieter
    Horber, Daniel
    Bastian, Sara
    Kueng, Marc
    Saletti, Piercarlo
    Helbling, Daniel
    Baertschi, Daniela
    Lugli, Alessandro
    Bernhard, Juerg
    Andrieu, Christiane
    von Moos, Roger
    JOURNAL OF GERIATRIC ONCOLOGY, 2019, 10 (02) : 304 - 310
  • [43] Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
    Kienle, D.
    Winterhalder, R.
    Koeberle, D.
    Horber, D.
    Kueng, M.
    Saletti, P.
    Helbling, D.
    Bastian, S.
    Dietrich, D.
    Baertschi, D.
    Pilop, C.
    Von Moos, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S194 - S195
  • [44] Maintenance treatment with capecitabine plus cetuximab after first-line standard fluorouracil-based chemotherapy plus cetuximab for patients with RAS wild-type advanced colorectal cancer.
    Yuan, Xianglin
    Zhao, Ben
    Qiu, Hong
    Zhang, Mingsheng
    Zou, Yanmei
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [45] Cetuximab (C225) in the first-line treatment of advanced colorectal cancer (CRC) patients (Pts) with K-ras wild-type (WT) tumors: Does the choice and schedule of fluoropyrimidine (Fp) matter?
    Ku, Geoffrey Yuyat
    Haaland, Benjamin
    Lopes, Gilberto de Lima
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [46] Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study
    Pinto, Carmine
    Di Fabio, Francesca
    Rosati, Gerardo
    Lolli, Ivan R.
    Ruggeri, Enzo M.
    Ciuffreda, Libero
    Ferrari, Daris
    Lo Re, Giovanni
    Rosti, Giovanni
    Tralongo, Paolo
    Ferrara, Raimondo
    Alabiso, Oscar
    Chiara, Silvana
    Ianniello, Giovanni P.
    Frassoldati, Antonio
    Bilancia, Domenico
    Campanella, Giovanna A.
    Signorelli, Carlo
    Racca, Patrizia
    Benincasa, Elena
    Stroppolo, Maria Elena
    Di Costanzo, Francesco
    CANCER MEDICINE, 2016, 5 (11): : 3272 - 3281
  • [47] Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial
    Venook, Alan P.
    Niedzwiecki, Donna
    Lenz, Heinz-Josef
    Innocenti, Federico
    Fruth, Briant
    Meyerhardt, Jeffrey A.
    Schrag, Deborah
    Greene, Claire
    O'Neil, Bert H.
    Atkins, James Norman
    Berry, Scott
    Polite, Blase N.
    O'Reilly, Eileen M.
    Goldberg, Richard M.
    Hochster, Howard S.
    Schilsky, Richard L.
    Bertagnolli, Monica M.
    El-Khoueiry, Anthony B.
    Watson, Peter
    Benson, Al B., III
    Mulkerin, Daniel L.
    Mayer, Robert J.
    Blanke, Charles
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (23): : 2392 - 2401
  • [48] Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES study).
    Normanno, Nicola
    Rachiglio, Anna Maria
    Abate, Riziero Esposito
    Orlandi, Armando
    Maiello, Evaristo
    Maglietta, Giuseppe
    Damato, Angela
    Maiello, Monica Rosaria
    Carotenuto, Marianeve
    Calegari, Maria Alessandra
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria Giulia
    Tamberi, Stefano
    Lonardi, Sara
    Avallone, Antonio
    Latiano, Tiziana Pia
    Tamburini, Emiliano
    Barone, Carlo Antonio
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Continued cetuximab in second-line treatment for patients with unresectable metastatic wild-type KRAS, NRAS, and BRAF colorectal cancer after disease progression during first-line cetuximab-based therapy
    Liu, Ying
    Wang, Feng
    Ma, Ning
    Xu, Shuning
    Qiao, Lei
    Li, Ke
    Kuang, Gaizhen
    Li, Danyang
    Liu, Yangyang
    Xiong, Yanyan
    Sun, Mingming
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [50] Multicenter phase II study of FOLFOX or biweekly XELOX and cetuximab as first-line treatment in patients with wild-type KRAS/BRAF metastatic colorectal cancer (mCRC) (FLEET study)
    Kim, Ho Min
    Soda, Hitoshi
    Hazama, Shoichi
    Takahashi, Takao
    Nagata, Naoki
    Kotaka, Masahito
    Kono, Emiko
    Terada, Itsurou
    Fukunaga, Mutsumi
    Oba, Koji
    Hasegawa, Junichi
    Sakamoto, Junichi
    Mishima, Hideyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
12345